Latest treatment of multiple sclerosis Stories

 Patients with multiple sclerosis who smoke appear to experience a more rapid progression of their disease, according to a report in the July issue of Archives of Neurology, one of the JAMA/Archives journals.Cigarette smokers are at higher risk of developing multiple sclerosis (MS), according to background information in the article. However, the effect of smoking on the progression of MS remains uncertain.Brian C. Healy, Ph.D., of Brigham and Women's Hospital, Harvard Medical School and...

Toronto Stock Exchange Symbol: MS EDMONTON, May 28 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Randy Stroud, Vice President Regulatory Affairs, will present at the Canadian Society for Pharmaceutical Sciences 12th Annual Meeting & Symposium. TITLE: "Dirucotide: A Potential Therapy for Multiple Sclerosis" WHEN: Thursday June 4th at 2:00 pm (Eastern Time)...

Toronto Stock Exchange Symbol: MS EDMONTON, May 11 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the first quarter, ended March 31, 2009. "We remain on track to obtain the results from MAESTRO-01, the first of our two pivotal trials evaluating dirucotide in patients with secondary progressive multiple sclerosis, in the second half of 2009," said Kevin Giese,...

Toronto Stock Exchange Symbol: MS EDMONTON, April 29 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at a session entitled "Leveraging on energy wealth: the development of a world class technology sector" as part of the Alberta Economic Forum in Geneva in Switzerland. WHEN: Monday May 4th at 10:05am (Local time) WHERE: Grand Hotel...

SEATTLE, April 29 /PRNewswire/ -- New analyses of data from the 16-Year Long-term Follow-up study with Betaseron(R) (interferon beta-1b), sponsored by Bayer HealthCare Pharmaceuticals, were presented at the American Academy of Neurology's (AAN) 61st Annual Meeting. The study results showed that early and sustained exposure to Betaseron in study participants with multiple sclerosis (MS) were more likely to avoid a negative clinical outcome as demonstrated years later.(1) In this study,...

Toronto Stock Exchange Symbol: MS EDMONTON, April 24 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Tony Hesby, Executive Vice President, will present at BioFinance 2009 in Toronto. WHEN: Wednesday April 29th at 11:00am (Eastern Time) WHERE: Toronto Marriott Eaton Centre Hotel (Trinity V room) 525 Bay Street Toronto, ON About BioFinance 2009...

Toronto Stock Exchange Symbol: MS EDMONTON, April 21 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's pivotal phase III MAESTRO-01 Canadian/European trial of dirucotide in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol. This was the final...

Only 39 Percent of Newly Diagnosed Patients Receive a Drug Within One Year of Their First Diagnosis, According to a New Report from Decision Resources WALTHAM, Mass., April 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed neurologists anticipate that less than 30 percent of their use of emerging oral agents --- Merck Serono's oral cladribine, Novartis/Mitsubishi Pharma's...

Toronto Stock Exchange Symbol: MS EDMONTON, April 14 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTRO-03 trial of dirucotide in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol. This was the fourth of several regularly...

Patients with multiple sclerosis (MS) may soon have more treatment options for their disease.A new report in Chemical & Engineering News says years of scientific research on MS means 11 potential new drugs are now in the final stages of clinical trials and may soon be on pharmacy shelves. Those drugs could double the number of medications available to treat MS over the next several years.Many of the new drugs are pills rather than injections. This makes it easier for patients to take the...